Ace2 Peptide Sars Cov Yrykyl

SARS-CoV-2 Spike Peptide

9083P 0.05 mg
EUR 235.5
Description: (NT) SARS-CoV-2 Spike peptide

Human IgG antibody Laboratories manufactures the ace2 peptide sars cov yrykyl reagents distributed by Genprice. The Ace2 Peptide Sars Cov Yrykyl reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Peptide. Other Ace2 products are available in stock. Specificity: Ace2 Category: Peptide Group: Sars Cov

PLPro Antibody (SARS-CoV)

250 µg
EUR 360
Description: Chicken polyclonal antibody recognizing the SARS-CoV Papain-like Protease (PLpro) as a 35 kDa protein. Purified from egg yolks. This antibody recognizes PLPro from both SARS-CoV-1 and SARS-CoV-2. Does not cross react with SARS-CoV 3CL protease.

SARS-CoV Matrix Antibody

0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Envelope Antibody

0.02 mg
EUR 206.18
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

SARS-CoV Envelope Antibody

0.1 mg
EUR 523.7
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

Sars Cov information

SARS-CoV-2 (COVID-19) Membrane Peptide

9157P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide

9165P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) Envelope Peptide

9169P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) Envelope Peptide

SARS-CoV-2 Spike Peptide

9083P 0.05 mg
EUR 235.5
Description: (NT) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide

9087P 0.05 mg
EUR 235.5
Description: (CT) SARS-CoV-2 Spike RBD peptide

SARS-CoV-2 Spike Peptide

9091P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide

9095P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Nucleocapsid Peptide

9099P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Nucleocapsid peptide

SARS-CoV-2 Nucleocapsid Peptide

9103P 0.05 mg
EUR 235.5
Description: (CT) SARS-CoV-2 Nucleocapsid peptide

SARS-CoV-2 (COVID-19) NSP14 (ExoN) Peptide

9185P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP14 (ExoN) Peptide

SARS-CoV-2 (COVID-19) NSP14 (ExoN) Peptide

9187P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP14 (ExoN) Peptide

SARS-CoV-2 (COVID-19) NSP13 (Helicase) Peptide

9181P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP13 (Helicase) Peptide

SARS-CoV-2 (COVID-19) NSP13 (Helicase) Peptide

9183P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP13 (Helicase) Peptide

SARS-CoV-2 Spike S2 Peptide

9119P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike S2 Peptide

9123P 0.05 mg
EUR 235.5
Description: (CT) SARS-CoV-2 Spike peptide

SARS-CoV-2 (COVID-19) 3CL-PRO (NSP5) Peptide

9151P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) 3CL-PRO (NSP5) Peptide

SARS-CoV-2 (COVID-19) 3CL-PRO (NSP5) Peptide

9153P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) 3CL-PRO (NSP5) Peptide